<DOC>
	<DOCNO>NCT02492256</DOCNO>
	<brief_summary>Although circumferential pulmonary vein isolation ( PVI ) consider cornerstone atrial fibrillation ablation , substantial recurrence rate . The investigator design prospectively randomize study evaluate whether additional atrial ganglionated plexi ablation guide SUMO technology improve clinical outcome patient persistent AF .</brief_summary>
	<brief_title>Atrial Ganglionated Plexi Ablation Guided SUMO Technology With Without Conventional Pulmonary Vein Isolation Patients With Persistent AF</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . Male female patient , age ≥ 18 ≤ 80 year . 2 . Persistent AF ( ECG documentation ) . 3 . Indication AF ablation . 4 . LVEF ≥ 50 % 5 . Able provide write informed consent 6 . Able comply requirement study 1 . Reversible cause atrial fibrillation 2 . Previous AF ablation therapy 3 . Clinical evidence active coronary ischemia , significant valvular heart disease , hemodynamically significant congenital cardiac abnormality 4 . Recent ( 3 month ) myocardial infarction ( MI ) , stroke transient ischemic attack ( except patient DES implant stent postMI would one year ) 5 . Contraindication Iodine123 Metaiodobenzylguanidine ( 123ImIBG ) , iodine , isoproterenol 6 . Use medication noncardiac medical condition know interfere 123ImIBG uptake safely withhold least 24 hour prior DSPECT study procedures 7 . Inability undergo DSPECT CT image</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>